Fredun Pharmaceuticals Ltd — Important, 15-05-2026: Company Update

Fredun Pharmaceuticals has launched "HORMONE RANGE PRODUCTS," a premium specialty therapeutics brand focused on longevity and human performance. This strategic entry into a high-growth healthcare segment aims to strengthen the company’s innovation-led portfolio. The doctor-led, evidence-backed platform offers therapies based on testosterone, nandrolone, and growth hormone solutions, emphasizing preventive care and high-margin categories with a digital-first patient engagement model. This expands Fredun’s reach for a comprehensive approach to wellness and performance therapeutics. For FY25, Fredun reported revenues of ₹ 456 Cr, EBITDA of ₹ 55 Cr, and PAT of ₹ 21 Cr.